EU/3/02/093: Orphan designation for the treatment of intestinal graft-versus-host disease

Beclomethasone 17, 21-dipropionate


On 13 March 2002, orphan designation (EU/3/02/093) was granted by the European Commission to Voisin Consulting, France, for beclomethasone 17,21-dipropionate (oral use) for the treatment of intestinal graft versus host disease (GvHD).

The sponsorship was transferred to DOR BioPharma UK Ltd, United Kingdom, in May 2008.

DOR BioPharma UK Ltd has changed its name to Soligenix UK Ltd in May 2011.

The sponsorship was transferred to Soligenix, the Netherlands, in June 2020.

Key facts

Active substance
Beclomethasone 17, 21-dipropionate
Intended use
Treatment of intestinal graft-versus-host disease
Orphan designation status
EU designation number
Date of designation

Soligenix NE B.V.
Joop Geesinkweg 901
1114 AB Amsterdam-Duivendrecht

Review of designation

This medicine is now known as beclometasone dipropionate.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating